Data evaluation of Ankara Numune Training and Education Hospital immunofixation electrophoresis

Abstract

Objective: The immunofixation electrophoresis (IFE) is a method used for the diagnosis, monitoring and treat­ment of monoclonal gammopathies (MG). The mono­clonal gammopathies include premalignant or malignant disease such as multiple myeloma, Waldenström\'s mak­roglobulinaemia (WM), plasmacytoma, monoclonal gam­mopati of undetermined significance (MGUS), plasma cell leukemia and amiloidosis (AL). We aimed to evaluate IFE reports analyzed in Ankara Numune Teaching and Re­search hospital from January to July 2011. Methods: IFE was studied by Interlab G26 in our labora­tory. In this study, all IFE reports examined which analyzed between January and July 2011. The results assessed for frequency and type of MG and also for diagnosis of the disease. Results: A total of 688 patients from January to July 2011 were studied by IFE and 126 (18.3%) patients have been identified as MG. There were 72 (57.1%) men and 54 (42.9%) women in patients with MG. Distribution of iso­types were IgG kappa 41.3%, IgG lambda 35.6%, IgA kappa 11.5%, IgA lambda 5.8%, IgM kappa 3.8% and IgM lambda 1.9%. There were MM (65.9%), WM (0.07%) and MGUS (33%) in patients with MG. Conclusion: IgG kappa was the most common type of MG and MM was the most common disease in these pa­tients. MG detection rate was 18% in patients requested IFE test. The decreased rate has shown that at first serum protein electrophoresis must studied and then IFE test must be performed in patients who have an uncertainty of MG. J Clin Exp Invest 2013; 4 (2):148-152

Keywords

• Monoclonal gammopathies, immunofixation electrophoresis, multiple myeloma

Ankara Numune Eğitim ve Araştırma Hastanesi immünfiksasyon elektroforezi verilerinin değerlendirilmesi

Abstract

Amaç: İmmünfiksasyon elektroforezi (IFE), monoklonal gammapatilerin (MG) tanı, takip ve tedavi sürecinin yön­lendirilmesinde kullanılan bir yöntemdir. Monoklonal gam­mapatiler; malignite potansiyeli olan ya da malign hasta­lıklardan multipl myelom (MM), Waldenstrom makroglo­bulinemisi (WM), soliter plazmositom, önemi bilinmeyen monoklonal gamapati (MGUS), plazma hücreli lösemi ve amiloidozu (AL) kapsamaktadır. Çalışmamızda, Ankara Numune Eğitim ve Araştırma Hastanesi Merkez Labora­tuvarında Ocak 2011 -Temmuz 2011 tarihleri arasında ça­lışılmış olan IFE verilerinin retrospektif olarak incelenerek sunulması amaçlanmıştır. Yöntemler: IFE laboratuvarımızda İnterlab G26 cihazın­da çalışılmaktadır. Çalışmamızda Ocak-Temmuz 2011 tarihleri arasında çalışılan tüm IFE sonuçları incelenmiş­tir. Sonuçlar MG sıklığı, MG türü ve hastaların aldığı tanı açısından değerlendirilmiştir. Bulgular: Ocak-Temmuz 2011 tarihleri arasında toplam 688 hastaya IFE yapılmış, 126 (%18,3)\'sında MG tespit edilmiştir. MG tespit edilen hastaların 72 (%57,1) \'si er­kek, 54 (%42,9)\'ü kadındı. İzotip dağılımları IgG kappa %41,3, IgG lambda %35,6, IgA kappa %11,5, IgA lambda %5,8, IgM kappa %3,8, IgM lambda %1,9 şeklindeydi. Hastaların tanıları; MM (%65,9), WM (%0.07) ve MGUS (%33) olarak belirlendi. Sonuç: MG tespit edilen hastalarda en sık görülen pa­tern IgG kappa idi. Hastaların en çok aldığı tanı ise MM idi. Laboratuarımıza IFE istemi ile başvuran hastalarda MG saptanma oranı ise %18 olarak bulundu. Bu oranın düşüklüğü, hastaların önce serum protein elektroforezi (SPE) ile değerlendirilip MG varlığı ya da şüphesinde IFE istemi yapılmasının önemini ortaya koymaktadır.

Keywords

• Monoklonal gammapati, immünfik­sasyon elektroforezi, multipl myelomJ Clin Exp Invest 2013;4(2):148-152

References

1. Öge AE PY. Polinöropatiler. İÜ İstanbul Tıp Fakültesi Temel ve Klinik Bilimler Ders Kitapları. 2004;1.bas- kı:591-625.
2. Koç H. Klinik Hematoloji Ders Kitabı. Ankara Üniversi- tesi Tıp Fakültesi Antıp AŞ. 1997:171-187.
3. Attaelmannan M, Levinson SS. Understanding and identifying monoclonal gammopathies. Clin Chem 2000;46:1230-1238.
4. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
5. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
6. Wadhera RK, Rajkumar SV. Prevalence of monoclonal gammopathy of undetermined significance: a system- atic review. Mayo Clin Proc 2010;85:933-942.
7. Alfonso E. Quantitation immunoelectrophoresis of se- rum proteins. Clin Chem Acta 1964;10:114-122.
8. Ritchie RF, Smith R. Immunofixation. I. General prin- ciples and application to agarose gel electrophoresis. Clin Chem 1976;22:497-499.

9. Alper CA JA. Immunofixation electrophoresis: A tech- nique fort the study of protein polymorphism. Vox Sang 1969;17:445-452.
10. Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med 1997;336:1657-1664.
11. Katzmann JA, Kyle RA, Benson J, et al. Screening panels for detection of monoclonal gammopathies. Clin Chem 2009;55:1517-1522.
12. Katzmann JA. Screening panels for monoclonal gammopathies: time to change. Clin Biochem Rev 2009;30:105-111.
13. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23:215-224.
14. Merlini G, Palladini G. Differential diagnosis of monoclonal gammopathy of undetermined signifi- cance. Hematology Am Soc Hematol Educ Program. 2012;2012:595-603.
15. Katzmann JA, Abraham RS, Dispenzieri A, et al. Diag- nostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem 2005;51:878-881.
16. Bradwell AR, Carr-Smith HD, Mead GP, et al. Serum test for assessment of patients with Bence Jones my- eloma. Lancet 2003;361:489-491.
17. Drayson M, Tang LX, Drew R, et al. Serum free light- chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001;97:2900-2902.
18. Dispenzieri A, Kyle RA, Katzmann JA, et al. Immuno- globulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008;111:785-789.
19. Lachmann HJ, Gallimore R, Gillmore JD, et al. Out- come in systemic AL amyloidosis in relation to chang- es in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003;122:78-84.
20. Bradwell AR. Serum free light chain measurements move to center stage. Clin Chem 2005;51:805-807.
21. Pratt G. The evolving use of serum free light chain assays in haematology. Br J Haematol 2008;141:413- 422.